Efficacy and Safety of Oral Kanglaite (KLTc) in Men With Prostate Cancer: Randomized, Dose-Ranging Study of the Effects of KLTc on Prostate Specific Antigen (PSA) Doubling Time Among Men With Rising PSA Levels After Definitive Local Therapy.
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2014
At a glance
- Drugs Kanglaite (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors KangLaiTe USA
- 10 Jun 2017 Biomarkers information updated
- 15 Jan 2014 According to ClinicalTrials.gov record; study status changed from active, no longer recruiting to discontinued.
- 06 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.